Immix Biopharma company info

What does Immix Biopharma do?
Immix Biopharma (NASDAQ:IMMX) is a biotech firm focused on developing and bringing innovative treatments to patients with unmet medical needs, particularly in the oncology and immunotherapy spaces. The company is actively working on several pioneering projects aimed at tackling some of the most challenging diseases by advancing their proprietary platforms and drug candidates through clinical trials. Their objective is to significantly improve patient outcomes by harnessing the power of cutting-edge science and targeted therapies. Through strategic partnerships and rigorous research and development efforts, Immix Biopharma strives to emerge as a key player in transforming the landscape of modern medicine and healthcare.
Immix Biopharma company media
Company Snapshot

Is Immix Biopharma a public or private company?

key
Ownership
Public

How many people does Immix Biopharma employ?

people
Employees
14

What sector is Immix Biopharma in?

pie chart
Sector
Health Care

Where is the head office for Immix Biopharma?

location pin
Head Office
Los Angeles, United States

What year was Immix Biopharma founded?

founded flag
Year Founded
2012
What does Immix Biopharma specialise in?
/Cancer Therapies /Immunotherapy Development /Biopharmaceutical Research /Clinical Trials /Drug Discovery /Innovation Science

What are the products and/or services of Immix Biopharma?

Overview of Immix Biopharma offerings
Imx-110: First-in-class therapeutic for solid tumors, utilizing a novel approach to target cancer.
Nanoparticle albumin-bound (nab) technology: Enhances delivery of chemotherapy drugs to improve cancer treatment effectiveness.
Imx-120: Innovative project focused on developing treatments for rare and difficult-to-treat cancers.
Collaborations with academic institutions: Partnerships to accelerate drug discovery and development processes.

Who is in the executive team of Immix Biopharma?

Immix Biopharma leadership team
  • Dr. Ilya  Rachman M.B.A., M.D., MBA, Ph.D.
    Dr. Ilya Rachman M.B.A., M.D., MBA, Ph.D.
    Co-Founder, CEO & Chairman
  • Mr. Gabriel  Morris B.A.
    Mr. Gabriel Morris B.A.
    CFO & Director
  • Mr. Sean  Senn J.D., M.B.A., M.Sc., MBA, MSc
    Mr. Sean Senn J.D., M.B.A., M.Sc., MBA, MSc
    Co-Founder
  • Dr. Vladimir P. Torchilin D.Sc., MSE, Ph.D.
    Dr. Vladimir P. Torchilin D.Sc., MSE, Ph.D.
    Scientific Co-Founder
  • Mr. Ben H. Lyon J.D.
    Mr. Ben H. Lyon J.D.
    Executive VP & General Counsel
  • Dr. Graham  Ross FFPM, M.D.
    Dr. Graham Ross FFPM, M.D.
    Chief Medical Officer & Head of Clinical Development
  • Mr. Nandan  Oza B.S.
    Mr. Nandan Oza B.S.
    Head of Chemistry, Manufacturing & Control
  • Dr. David  Marks
    Dr. David Marks
    Chief Medical Officer of Cell Therapy